@misc{indiciae1b1b02ad3921,
  title = {Primary CD34+ cells of patients with VEXAS syndrome are highly sensitive to targeted treatment with TAK-243 and pevonedistat},
  author = {Nowak, D. and Demmerle, M. and Klär, A. and Streuer, A. and Riabov, V. and Altrock, E. and Rapp, F. and Belzer, A.-C. and Klink, T. and Hahn, M. and Hofmann, F. and Nowak, V. and Weimer, N. and Obländer, J. and Palme, I. and Göl, M. and Darwich, A. and Steiner, L. and Abba, M. and Metzgeroth, G. and Hofmann, W.-K. and Schmitt, N.},
  year = {2025},
  doi = {10.1101/2025.05.22.653244},
  url = {https://www.biorxiv.org/content/10.1101/2025.05.22.653244v1},
  note = {Source identifier: 10.1101/2025.05.22.653244}
}